Clinical Trial Update: Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating empagliflozin for improving functional capacity in heart failure with preserved ejection fraction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic | Phase 4 | Status: COMPLETED